---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-039363"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:51:41.652231+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics closes $2.0M registered direct offering of 2.86M shares at $0.70 plus warrants

## Summary
- Gross proceeds of ~$2.0M from sale of 2,857,144 shares at $0.70 each; used for working capital.
- Warrants issued: 2,857,144 shares at $0.85, exercisable 6 months from issuance, 5.5-year term.
- Placement agent: H.C. Wainwright & Co. — 7% cash fee, 5% warrant coverage at $0.875 per share.
- Company suspended its existing ATM equity program pending new prospectus supplement.
- Offering closed April 2, 2026 as announced in a separate press release.

## SEC filing metadata
- accession: 0001213900-26-039363
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390026039363/0001213900-26-039363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390026039363/ea0284778-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-039363
- JSON: https://secwatch.observer/filing/0001213900-26-039363.json
- Plain text: https://secwatch.observer/filing/0001213900-26-039363.txt

## Source-grounded claims
- claim_id: e9c0295a9e2c34ecce9ccb08901268aa47a4b662
  claim: Hoth Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at Company agreed to sell 2,857,144 shares of common stock at $0.70 per share; gross proceeds approxima (effective 2026-04-01).
  evidence_excerpt: On April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,144 shares (the “Shares”) of common stock of the Company (the “Common Stock”), at a purchase price of $0.70 per share of Common Stock (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390026039363/0001213900-26-039363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.